Skip to main content

JAK/TYK2

RheumNow Podcast square
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-OPTIMISE:…
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)

The evidence-based recommendation

Dr. John Cush RheumNow

3 months 2 weeks ago
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC)

Dr. Robert Chao reviews a talk given by Dr. Lau

Dr. John Cush RheumNow

3 months 2 weeks ago
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
PSA068.jpg
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of…
joint.wrist_.pain_.CTS_.Carpal.jpg
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require…
RT @ERheumat: @IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASD

EnvisionRheumat ERheumat

3 months 2 weeks ago
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT
RT @MeralElRamahiMD: ⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
RT @Stiddyo: @DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet cl

Paul Studenic Stiddyo

3 months 2 weeks ago
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow
RT @Janetbirdope: tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. De

Janet Pope Janetbirdope

3 months 2 weeks ago

tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. Deficiency of TYK2 gives less autoimmune diseases. @RheumNow @eular_org #EULAR2021 BMS Tyk Talk symposium https://t.co/knP9n0Qc0u

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb,

Dr. John Cush RheumNow

3 months 2 weeks ago

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

×